27984919|t|From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?
27984919|a|The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.
27984919	5	17	chemotherapy	T061	C3665472
27984919	21	27	target	T169	C1521840
27984919	28	37	therapies	T061	C0087111
27984919	38	53	associated with	T080	C0332281
27984919	54	63	radiation	T070	C0851346
27984919	71	80	treatment	T169	C0039798
27984919	84	89	NSCLC	T191	C0007131
27984919	93	109	durable marriage	T061	C4264454
27984919	115	126	integration	T169	C0205245
27984919	135	147	radiotherapy	T170	C0034619
27984919	152	157	drugs	T061	C3687832
27984919	164	176	chemotherapy	T061	C3665472
27984919	189	198	available	T169	C0470187
27984919	199	205	target	T169	C1521840
27984919	206	215	therapies	T061	C0087111
27984919	237	245	relevant	T080	C2347946
27984919	258	267	treatment	T169	C0039798
27984919	279	287	advanced	T080	C0205179
27984919	292	302	metastatic	T169	C0036525
27984919	303	329	Non-small cell lung cancer	T191	C0007131
27984919	331	336	NSCLC	T191	C0007131
27984919	339	342	Aim	T078	C1947946
27984919	358	364	review	T170	C0282443
27984919	371	379	evaluate	T058	C0220825
27984919	407	418	application	T169	C4048755
27984919	431	442	interaction	T169	C1704675
27984919	455	460	drugs	T061	C3687832
27984919	469	479	modalities	T078	C0695347
27984919	483	495	radiotherapy	T170	C0034619
27984919	515	523	searched	T052	C1706202
27984919	524	531	Medline	T170	C0025141
27984919	533	547	Google Scholar	T170	C0242356
27984919	549	555	PubMed	T170	C1138432
27984919	557	578	ProQuest Dissertation	T170	C0242356
27984919	591	600	databases	T170	C0242356
27984919	605	612	reports	T170	C0684224
27984919	613	622	published	T057	C0034037
27984919	626	633	English	T171	C0376245
27984919	637	642	study	T062	C2603343
27984919	647	655	included	T169	C0332257
27984919	676	703	cancer-related radiotherapy	T170	C0034619
27984919	708	716	included	T169	C0332257
27984919	717	725	patients	T101	C0030705
27984919	731	736	NSCLC	T191	C0007131
27984919	737	749	treated with	T061	C0332293
27984919	750	755	chemo	T061	C3665472
27984919	763	769	target	T169	C1521840
27984919	770	779	therapies	T061	C0087111
27984919	781	796	Review articles	T170	C0282443
27984919	802	810	excluded	T078	C1554077
27984919	820	828	analysis	T062	C0936012
27984919	849	867	Chemo-radiotherapy	T061	C4264454
27984919	874	884	represents	T052	C1882932
27984919	889	897	standard	T080	C1442989
27984919	901	907	choice	T052	C1707391
27984919	919	927	advanced	T080	C0205179
27984919	928	933	NSCLC	T191	C0007131
27984919	944	948	date	T079	C0011008
27984919	965	971	target	T169	C1521840
27984919	972	981	therapies	T061	C0087111
27984919	985	1003	chemo-radiotherapy	T061	C4264454
27984919	1028	1034	robust	T080	C2986815
27984919	1053	1069	stage of disease	T060	C0699749
27984919	1087	1094	absence	T169	C0332197
27984919	1098	1126	randomized controlled trials	T062	C0206035
27984919	1140	1146	target	T169	C1521840
27984919	1147	1156	therapies	T061	C0087111
27984919	1160	1171	early stage	T079	C2363430
27984919	1172	1180	adjuvant	T169	C1522673
27984919	1181	1186	NSCLC	T191	C0007131
27984919	1198	1209	recommended	T078	C0034866
27984919	1213	1230	clinical practice	T170	C0282574
27984919	1267	1282	oligometastatic	T191	C0027627
27984919	1287	1311	oligoprogressive disease	T191	C0027627
27984919	1317	1326	molecules	T167	C0567416
27984919	1355	1364	effective	T080	C1704419
27984919	1402	1413	application	T169	C4048755
27984919	1426	1437	interaction	T169	C1704675
27984919	1450	1455	drugs	T061	C3687832
27984919	1464	1474	modalities	T078	C0695347
27984919	1478	1490	radiotherapy	T170	C0034619